Published in Am J Gastroenterol on June 02, 2009
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol (2016) 1.32
The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology (2011) 1.18
Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther (2009) 1.16
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment Pharmacol Ther (2010) 0.89
Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study. Glob Adv Health Med (2014) 0.89
Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med (2014) 0.88
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health (2010) 0.85
Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes (2015) 0.83
Change in Quality of Life for Patients with Irritable Bowel Syndrome following Referral to a Gastroenterologist: A Cohort Study. PLoS One (2015) 0.83
Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. Eur J Health Econ (2012) 0.77
Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol (2016) 0.76
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Methods to explain the clinical significance of health status measures. Mayo Clin Proc (2002) 7.00
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci (1998) 3.74
The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 3.25
Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther (2002) 1.97
The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther (2004) 1.76
Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol (2003) 1.59
The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther (2004) 1.55
Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol (2007) 1.54
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol (2007) 1.44
Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics (2002) 1.44
Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci (1995) 1.35
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.28
Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more? Psychosom Med (2006) 1.20
Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord (2003) 1.08
The relationship between health perception and utility in heart failure patients in a clinical trial: results from an OVERTURE substudy. J Card Fail (2004) 0.96
Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther (2007) 0.94
Health-related quality of life: a primer for gastroenterologists. Am J Gastroenterol (1999) 0.88
Functional bowel disorders. Gastroenterology (2006) 20.72
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol (2013) 4.24
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology (2006) 2.95
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology (2006) 2.68
Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58
Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain (2005) 2.51
Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology (2003) 2.32
Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology (2013) 2.26
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol (2006) 2.14
The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J (2011) 2.08
Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol (2010) 2.02
Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun (2004) 1.98
Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial. Gastroenterology (2006) 1.94
Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc (2005) 1.88
A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2009) 1.85
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol (2006) 1.83
Psychometric properties of the Early Trauma Inventory-Self Report. J Nerv Ment Dis (2007) 1.81
Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain (2013) 1.77
Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology (2010) 1.75
Generation of PPARγ mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning. Cell Res (2011) 1.74
Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol (2009) 1.73
The brain-gut axis in abdominal pain syndromes. Annu Rev Med (2011) 1.68
The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol (2002) 1.67
The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med (2007) 1.65
The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol (2009) 1.65
Gut/brain axis and the microbiota. J Clin Invest (2015) 1.64
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. J Neurosci (2005) 1.60
Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol (2009) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Development and validation of a novel patient educational booklet to enhance colonoscopy preparation. Am J Gastroenterol (2011) 1.52
Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.52
Ischemic colitis as a cause of severe hematochezia: risk factors and outcomes compared with other colon diagnoses. Gastrointest Endosc (2011) 1.51
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Dialysis practices that distinguish facilities with below- versus above-expected mortality. Clin J Am Soc Nephrol (2010) 1.50
Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol (2003) 1.50
Clinical predictors of Barrett's esophagus length. Gastrointest Endosc (2005) 1.45
Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain. Pain (2013) 1.45
American Gastroenterological Association medical position statement on constipation. Gastroenterology (2013) 1.44
Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol (2008) 1.44
Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol (2009) 1.42
Impact of Mindfulness-Based Stress Reduction training on intrinsic brain connectivity. Neuroimage (2011) 1.42
Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res (2003) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Functional Somatic Syndromes: Emerging Biomedical Models and Traditional Chinese Medicine. Evid Based Complement Alternat Med (2004) 1.39
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology (2013) 1.38
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.35
Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res (2010) 1.34
Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology (2009) 1.33
Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology (2009) 1.33
The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage (2006) 1.32
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.28
Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med (2009) 1.28
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant (2005) 1.28
The effect of life stress on symptoms of heartburn. Psychosom Med (2004) 1.28
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol (2004) 1.27
Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol (2003) 1.27
The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol (2010) 1.26
Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences. Psychosom Med (2014) 1.24
Sex-based differences in gastrointestinal pain. Eur J Pain (2004) 1.23
Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology (2011) 1.22
Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol (2004) 1.20
The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology (2011) 1.18
Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. Endocrinology (2014) 1.18
Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am (2011) 1.15
Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis. EMBO J (2013) 1.15
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc (2005) 1.12
Patients with chronic visceral pain show sex-related alterations in intrinsic oscillations of the resting brain. J Neurosci (2013) 1.11
Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology (2009) 1.11